Skip to content
Medical Health Aged Care

Students to compete at National Pharmacy Competition

Pharmaceutical Society of Australia (PSA) 2 mins read

The Pharmaceutical Society of Australia (PSA) today announced the state and territory finalists for the 2023 Viatris Pharmacy Student of the Year (PSOTY) award, with the prestigious national final to take place at PSA’s National Conference PSA23 in July.

During the national final, students will be tested with a real-life clinical situation, where a patient will present with symptoms or a specific product request. Students are then required to use their clinical knowledge and communication skills to identify the most appropriate course of over-the-counter treatment, tailoring their response to provide the most appropriate advice.

A judging panel assesses all state finalists before selecting the national winner to be announced at PSA23’s Gala Dinner.

PSA National President Dr Fei Sim FPS congratulated the finalists, saying that the awards encourage students to draw on their clinical knowledge and emotional intelligence to demonstrate their skills.

“The Pharmacy Student of the Year awards showcase the skills and abilities of some of our outstanding pharmacy students to the broader profession, while also giving students a chance to apply their skills and be judged on them.

“Award sponsor Viatris and PSA are proud to sponsor the finalists to attend PSA23, providing travel and accommodation to ensure that they can get the most out of the leading pharmacist education conference.

“The Pharmacy Student of the Year will also receive a $3,000 cash prize to support their studies and pharmacy careers.

“Congratulations to all the students who’ve participated in the competition this year for their hard work and commitment to pharmacy.

“It’s exciting to see such talented students entering our profession and dedicating their lives to the health and wellbeing of their communities,” Dr Sim said.

The 2023 PSA Viatris Pharmacy Student of the Year finalists are:

  • Jamie-Lee Carew, the University of Newcastle
  • Sarah Foster, LaTrobe University
  • Kennith Lam, Curtin University
  • Samantha Montgomery, Queensland University of Technology
  • Claire Ryan, University of Tasmania
  • Brett Spicer, University of Canberra
  • Amelia Thompson, University of South Australia

They will also be joined by Ingrid Stoud from the University of Canberra, who was awarded the Wildcard winner at the 2023 National Australian Pharmacy Students Association Congress in January.

PSA extends thanks to the PSOTY award sponsor, Viatris, for their ongoing support and wishes all finalists the best of luck at the national final.


Media contact:   Georgia Clarke   M: 0410 505 315  E:

The Pharmaceutical Society of Australia is the only national peak body that represents all of Australia’s pharmacists across all practice settings. We want every Australian to have access to the best healthcare, and this must include optimising access to pharmacists’ knowledge and medicines expertise at the forefront of our healthcare system.


More from this category

  • Medical Health Aged Care
  • 29/05/2024
  • 17:07
JJP Biologics

JJP Biologics Announces Positive Decision to Execute a First-in-Human Clinical Trial of Anti-Inflammatory mAb JJP-1212 (anti-CD89)

JJP Biologics has received a positive conclusion on the Clinical Trial Application assessment for a Phase I Study of a potential first-in-class anti-CD89 antagonist,…

  • Contains:
  • Medical Health Aged Care
  • 29/05/2024
  • 11:54

Long-term prescription opioid use after hospital declining: study

UNSW Sydney medical researchers have shed light on post-hospital prescription opioid use. A large, linked data study has detailed the scale of prescription opioid…

  • Contains:
  • Medical Health Aged Care
  • 29/05/2024
  • 11:45
Cleo Diagnostics Limited ASX.COV

Cleo’s Ovarian Cancer Blood Test Outperforms Current Clinical Benchmark

Highlights A benchmarking study comparing CLEO’s ovarian cancer blood test against ultrasound has been published in scientific journal “Cancers” The study confirmed that CLEO’s initial test for the surgical triage market:– Significantly outperforms current clinical workflows that use CA125 and ultrasound to predict malignancy;– Correctly detected 90% of early-stage cancers compared to only 50% using standard workflows; and– Can be easily adopted for use into clinical practice. The superior performance of CLEO’s test now compared to all current routine clinical tools shows the significant global potential for the test in clinical decision making prior to surgical intervention. MELBOURNE, AUSTRALIA, 29…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.